Paper41805397
A two-center comparison of the efficacy of methylene blue and hydroxocobalamin for the treatment of refractory shock.
Leung NY and 4 others. Perfusion, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. A two-center comparison of the efficacy of methylene blue and hydroxocobalamin for the treatment of refractory shock. Papers, record 41805397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41805397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A two-center comparison of the efficacy of methylene blue and hydroxocobalamin for the treatment of refractory shock.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hydroxocobalamin | Major topic |
| Methylene Blue | Major topic |
| Shock | Major topic |
| Vasoconstrictor Agents | Major topic |
| Humans | |
| Female | |
| Retrospective Studies | |
| Male | |
| Middle Aged | |
| Aged | |
| Hospital Mortality |
Source PubMed
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22911566 | Survival after shock requiring high-dose vasopressor therapy. | Chest | 2013 | https://conductscience.org/library/papers/22911566 | PubMed |
| 2 | 36505110 | Methylene Blue in Refractory Shock. | Cureus | 2022 | https://conductscience.org/library/papers/36505110 | PubMed |
| 3 | 36915146 | Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. | Crit Care | 2023 | https://conductscience.org/library/papers/36915146 | PubMed |
| 4 | 33220576 | Vasopressor dose equivalence: A scoping review and suggested formula. | J Crit Care | 2021 | https://conductscience.org/library/papers/33220576 | PubMed |
| 5 | 18768890 | Endogenous hydrogen sulfide regulates inflammatory response by activating the ERK pathway in polymicrobial sepsis. | J Immunol | 2008 | https://conductscience.org/library/papers/18768890 | PubMed |
| 6 | 19917106 | Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. | Crit Care | 2009 | https://conductscience.org/library/papers/19917106 | PubMed |
| 7 | 37586951 | Hydroxocobalamin Versus Methylene Blue for the Treatment of Vasoplegic Shock Associated With Cardiopulmonary Bypass. | J Cardiothorac Vasc Anesth | 2023 | https://conductscience.org/library/papers/37586951 | PubMed |
| 8 | 20109575 | A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. | Nitric Oxide | 2010 | https://conductscience.org/library/papers/20109575 | PubMed |
| 9 | 8844239 | The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. | Intensive Care Med | 1996 | https://conductscience.org/library/papers/8844239 | PubMed |
| 10 | 28062334 | Intensity of Vasopressor Therapy for Septic Shock and the Risk of In-Hospital Death. | J Pain Symptom Manage | 2017 | https://conductscience.org/library/papers/28062334 | PubMed |
| 11 | 37225547 | Hydroxocobalamin in Refractory Vasodilatory Shock: More Questions than Answers. | J Cardiothorac Vasc Anesth | 2023 | https://conductscience.org/library/papers/37225547 | PubMed |
| 12 | 36174744 | High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial). | Chest | 2023 | https://conductscience.org/library/papers/36174744 | PubMed |
| 13 | 37265888 | Hydroxocobalamin as Rescue Therapy in a Patient With Refractory Amlodipine-Induced Vasoplegia. | Cureus | 2023 | https://conductscience.org/library/papers/37265888 | PubMed |
| 14 | 12519925 | The pathophysiology and treatment of sepsis. | N Engl J Med | 2003 | https://conductscience.org/library/papers/12519925 | PubMed |
| 15 | 30231909 | Refractory septic shock: our pragmatic approach. | Crit Care | 2018 | https://conductscience.org/library/papers/30231909 | PubMed |
| 16 | 24151551 | Therapeutic strategies for high-dose vasopressor-dependent shock. | Crit Care Res Pract | 2013 | https://conductscience.org/library/papers/24151551 | PubMed |
| 17 | 37147207 | Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic Review With Meta-Analysis for Comparison to Methylene Blue. | J Cardiothorac Vasc Anesth | 2023 | https://conductscience.org/library/papers/37147207 | PubMed |
| 18 | 33455885 | Methylene Blue for Vasoplegia During Extracorporeal Membrane Oxygenation Support. | J Cardiothorac Vasc Anesth | 2021 | https://conductscience.org/library/papers/33455885 | PubMed |
| 19 | 28528561 | Angiotensin II for the Treatment of Vasodilatory Shock. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28528561 | PubMed |
| 20 | 34176677 | Hydroxocobalamin or Methylene Blue for Vasoplegic Syndrome in Adult Cardiothoracic Surgery. | J Cardiothorac Vasc Anesth | 2022 | https://conductscience.org/library/papers/34176677 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41805397
GET https://conductscience.org/api/papers/v1/41805397/references?page=2